

1 Rapid communication

2

3

4 **Reliable transfection of *Plasmodium falciparum* using non-commercial plasmid**
5 **mini preparations**

6

7

8

9 Tobias Spielmann*, Matthew W.A. Dixon, Maria Hernandez-Valladares, Mandy Hannemann,

10 Katharine R. Trenholme, and Donald L. Gardiner

11

12

13 Infectious Diseases and Immunology Division, Queensland Institute of Medical Research, PO
14 Royal Brisbane Hospital, QLD 4029, Australia.

15

16

17

18

19

20

21

22

23 *Corresponding author. E-mail address: Tobias.Spielmann@gmail.com

24

25

26

27 **Abstract**

28 Transfection of *Plasmodium falciparum* is instrumental in the research of this parasite. However the
29 actual transfection protocol has not changed significantly since the first description and it is
30 generally believed that large amounts of highly pure plasmid DNA are needed for successful
31 transfection. Here we report the transfection of *P. falciparum* using a protocol based on non-
32 commercial minipreparations of plasmid DNA. This method permits the reliable transfection of *P.*
33 *falciparum* using less resources and costs with a success rate comparable to currently used methods.
34 A moderate throughput may be achieved using this method, providing a first step towards
35 systematic transfection approaches in this parasite.

36
37 *Keywords:* Malaria, *Plasmodium falciparum*, transfection

38
39
40 The development of the transfection technology for *Plasmodium* has greatly increased our
41 understanding of malaria parasites. However, despite the progress in vector development, reflected
42 by a growing number of validated promoters, reporters and selectable markers (Cowman and Crabb,
43 2005; Gardiner et al., 2003), the actual transfection procedure most commonly used for *P.*
44 *falciparum* has not changed significantly since its first description (Wu et al., 1995), and
45 transfection of *P. falciparum* is still considered a very difficult technique. The low efficiency of
46 transfection and the long selection times to obtain episomally transfected parasites has hampered
47 further development of the actual transfection protocol, as testing different conditions is very time
48 consuming. This has caused a certain mystification of the procedure and there is anecdotal evidence
49 for small changes in the actual protocol that are believed to increase the success rate of transfections
50 as well as to reduce selection times. However, it is generally believed that large amounts of highly
51 pure plasmid DNA (usually prepared using commercial maxiprep kits) are required which then have
52 to be transfected into often large *P. falciparum* culture volumes. By the time selection is applied (48
53 hours after transfection) this results in often considerable culture volumes for each single

54 transfection [10-30ml culture (Skinner-Adams et al., 2003b)] that then have to be maintained for
55 weeks. This incurs significant cost as well as handling time, especially if many transfections have to
56 be performed. However, often several constructs have to be tested, for instance to obtain adequate
57 expression of transgenic GFP fusion proteins, as the transgenic protein might not be tolerated if
58 expressed too highly or during the wrong parasite stage. Gateway technology (Invitrogen) allows
59 the generation of different plasmids with different promoters or tags in a short time (Skinner-Adams
60 et al 2003a; van Dooren et al., 2005), making transfection the actual rate-limiting step for such tests.
61 Also, systematic approaches for gene tagging and gene targeting would currently need vast
62 resources and the presently used methods are not suitable to achieve even a medium throughput.

63

64 We have developed a transfection protocol based on non-commercial plasmid mini preparations
65 transfected into 250µl infected red blood cells (corresponding to 5 ml of *P. falciparum* culture) that
66 shows a comparable success rate to methods using commercial maxi preparations and larger culture
67 volumes. Drug pressure was applied 6-12 hours after transfection (Voss *et al.* 2006), thereby
68 reducing the number of gametocytes formed and avoiding expansion of the culture volume
69 (transfections were also successful if the drug was added immediately after transfection, although
70 this was not extensively tested). The mini preparation protocol can also be used to conveniently
71 produce plasmids for DNA sequencing. Once the plasmid has been confirmed to contain no
72 mutations, the remaining plasmid can then be transfected. We successfully used this mini
73 preparation transfection method (MiPreT) for a number of constructs that are based on different
74 transfection vectors and many constructs were tested several times. Resistant parasites usually
75 reached 1% parasitemia between 20 and 35 days after transfection. An estimation of the time after
76 transfection until cultures reached 1% revealed a mean of 27.5 days for the MiPreT method (10
77 individual transfections). This is comparable to selection times observed in our laboratory using
78 maxi preparation transfection methods (MaxPreT) (Skinner-Adams et al., 2003b). There was no
79 difference between the time constants of MiPreT and MaxPreT transfections with constants of 0.6-

80 1.0 recorded for both of the methods with no discernable pattern. Plasmids that required very long
81 selection times using MaxPreT (presumably due to adverse effects of the transgene on the
82 parasites), were also successfully transfected using MiPreT. Although transfected parasites were
83 never obtained for certain plasmids, transfections with these plasmids were also always
84 unsuccessful when MaxPreT was used. These constructs were designed to mediate expression of
85 GFP-fusion proteins of early transcribed membrane proteins (ETRAMP) (Spielmann et al., 2003)
86 under the control of the *hsp86* promoter and might have been deleterious to the parasites. Thus the
87 success rate of the method presented here is comparable to using plasmids prepared from
88 commercial maxi preparations.

89
90 To further compare MiPreT and MaxPreT, we transfected 3D7 parasites from the same culture side
91 by side using two previously described plasmids. Plasmid 1 was based on vector pHHC*/DR0.28
92 (O'Donnell et al., 2002) and mediates expression of a myc-tagged ETRAMP4 (ETRAMP4myc)
93 under the control of the *hsp86* promoter (Spielmann et al., 2006). The second plasmid was vector
94 pARL, which mediates expression of GFP under the *crt* promoter (Crabb et al., 2004). All
95 transfections were successful and 1% parasitemia was reached 22-29 days after transfection (table
96 1). The transgene was expressed in parasites obtained by the MiPreT method as evident from
97 immunofluorescence assays or fluorescence of live parasites (Figure 1). To reproduce these results
98 we chose a different commonly used parasite strain (D10) and repeated the side by side test of
99 MiPreT and MaxPreT. Again none of the transfections failed and 1% parasitemia was reached
100 between 24-34 days after transfection. These side by side tests further confirmed our previous
101 results that the performance of MiPreT and MaxPreT are comparable.

102
103 To assess the viability of transfections utilizing MiPreT, vector integrity was confirmed. Stability of
104 the vector from both transfection methods was verified using both vector rescues and Southern
105 blotting (Figure 2). Genomic DNA (gDNA) was extracted from the following transfections

106 3D7pARL MaxPreT, D10pARL MiPreT, 3D7 ETRAMP4myc MiPreT and D10 ETRAMP4myc
107 MaxPreT. The gDNA was digested with *EcoRI* and *EcoRV* and probed with hDHFR. The Probe
108 specifically hybridised to a 1900kb band in all pARL and ETRAMP4myc transfected lines, this size
109 is consistent with the expected restriction pattern for episomally maintained vector (Figure 2 A).
110 For vector rescue, precipitated gDNA from the transfected parasites was transformed into *E. coli*
111 and plasmid DNA was extracted. The plasmids were then digested using *BglIII* and *EcoRV* and
112 compared to un-transfected vector. All rescued plasmids tested showed an identical digestion
113 pattern to un-transfected vector (Figure 2 B).

114

115 The MiPreT method was then used to assess the localization of two members of the ETRAMP
116 family that have not previously been localized (Spielmann et al., 2003). The full length coding
117 sequences of *etramp5* (PFE1590w) and *etramp11.1* (PF11_0039) were cloned into the
118 pHHC*/DR0.28 vector containing a myc tag as previously described for *etramp4* (Spielmann et al.,
119 2006). This resulted in vectors pHHC*/DR0.28-ETRAMP5myc and pHHC*/DR0.28-
120 ETRAMP11myc which were transfected into 3D7 parasites using the MiPreT method. The resultant
121 parasite lines ETRAMP5myc and ETRAMP11.1myc were analysed in immunofluorescence assays
122 using anti-myc antibodies (Figure 3). Both myc-tagged proteins were detected in a peripheral stain
123 around the parasite similar to previously analysed ETRAMP members (Spielmann et al., 2003;
124 Spielmann et al., 2006). This suggests that these ETRAMP members also reside in the
125 parasitophorous vacuole membrane and further demonstrates the usefulness of the MiPreT method.

126

127 Presently it is generally accepted that large amounts of highly pure DNA is required for successful
128 *P. falciparum* transfection. However, our results show that a cheap and simple plasmid preparation
129 is sufficient to achieve reliable transfection of this parasite. The comparatively small parasite
130 culture volumes and the method to prepare plasmid DNA might even be suitable for automation.
131 We hope that this will encourage further efforts to simplify this important technique. Moreover this

132 method provides a significant step towards high throughput approaches to enable systematic
133 targeting of *P. falciparum* gene function, which will be the logical next step in the post-genomic era
134 of this parasite.

135

136

137

138 **Acknowledgements**

139 We thank Drs. Alan Cowman, Brendan Crabb and Akin Adisa for vectors. T. S. is supported by a
140 fellowship from the Swiss National Science Foundation. M.D. is supported by an ANZ Trustees
141 PHD scholarship. K. T and D. G are supported by NHMRC program grant number 290208 and by a
142 generous donation from Mark Nicholson, Alice Hill and the Tudor Foundation. M.H.-V. was
143 supported by a Human Frontiers Science Program short-term fellowship.

144

145 **References**

146 Cowman, A.F., and Crabb, B.S. 2005. Genetic manipulation of *Plasmodium falciparum*. In:
147 Sherman, I.W., (Ed.), Molecular Approaches to Malaria, ASM Press, Washington DC pp.
148 50-67.

149 Crabb, B.S., Rug, M., Gilberger, T.W., Thompson, J.K., Triglia, T., Maier, A.G., Cowman, A.F.,
150 2004. Transfection of the human malaria parasite *Plasmodium falciparum*. Methods Mol
151 Biol 270, 263-276.

152 Gardiner, D.L., Skinner-Adams, T.S., Spielmann, T., Trenholme, K.R., 2003. Malaria transfection
153 and transfection vectors. Trends Parasitol 19, 381-383.

154 Hawthorne P.L, Trenholme K.R, Skinner-Adams T.S, Spielmann T, Fischer K, Dixon M.W.A,
155 Ortega M.R, Anderson K.L, Kemp D.J, Gardiner D.L. 2004. A novel *Plasmodium*
156 *falciparum* Ring Stage Protein, Rex, is located in Maurer's Clefts. Mol Biochem Parasitol
157 136, 181–189.

158 O'Donnell, R.A., Freitas-Junior, L.H., Preiser, P.R., Williamson, D.H., Duraisingh, M., McElwain,
159 T.F., Scherf, A., Cowman, A.F., Crabb, B.S., 2002. A genetic screen for improved plasmid
160 segregation reveals a role for Rep20 in the interaction of *Plasmodium falciparum*
161 chromosomes. EMBO J 21, 1231-1239.

162 Skinner-Adams, T.S., Hawthorne, P.L., Trenholme, K.R., Gardiner, D.L., 2003a. GATEWAY
163 vectors for *Plasmodium falciparum* transfection. Trends Parasitol 19, 17-18.

164 Skinner-Adams, T.S., Lawrie, P.M., Hawthorne, P.L., Gardiner, D.L., Trenholme, K.R., 2003b.
165 Comparison of Plasmodium falciparum transfection methods. Malar J 2, 19.

166 Spielmann, T., Ferguson, D.J., Beck, H.P., 2003. *etramps*, a new *Plasmodium falciparum* gene
167 family coding for developmentally regulated and highly charged membrane proteins located
168 at the parasite-host cell interface. Mol Biol Cell 14, 1529-1544.

169 Spielmann, T., Gardiner, D.L., Beck, H.P., Trenholme, K.R., Kemp, D.J., 2006. Organization of
170 ETRAMPs and EXP-1 at the parasite-host cell interface of malaria parasites. Mol Microbiol
171 59, 779-794.

172 van Dooren, G.G., Marti, M., Tonkin, C.J., Stimmler, L.M., Cowman, A.F., McFadden, G.I., 2005.
173 Development of the endoplasmic reticulum, mitochondrion and apicoplast during the
174 asexual life cycle of *Plasmodium falciparum*. Mol Microbiol 57, 405-419.

175 Voss TS, Healer J, Marty AJ, Duffy MF, Thompson JK, Beeson JG, Reeder JC, Crabb BS,
176 Cowman AF. 2006. A var gene promoter controls allelic exclusion of virulence genes in
177 *Plasmodium falciparum* malaria. Nature. Feb 23;439(7079):1004-8.

178 Wu, Y., Sifri, C.D., Lei, H.H., Su, X.Z., Wellems, T.E., 1995. Transfection of Plasmodium
179 falciparum within human red blood cells. Proc Natl Acad Sci U S A 92, 973-977.

180

181 **Figure Legend**

182 **Fig. 1.** Transgene expression in 3D7 parasites transfected using MiPreT. **A.** Detection of
183 ETRAMP4myc in acetone fixed cells using an anti-myc antiserum. The green anti-myc stain (myc)

184 overlaid with Hoechst stained nuclei (n) shows the typical staining pattern for ETRAMP4. **B.** GFP
185 fluorescence in the parasite cytoplasm in live parasites. GFP fluorescence in the parasite cytoplasm
186 is seen in a single and a triple infected red blood cell. bf, bright field; n, nuclei. Size bars, 5µm.

187 MaxPreT transfections were done using Maxiprep DNA (Qiagen) as described (Skinner-Adams et
188 al., 2003b) using previously described electroporation conditions (Wu et al., 1995). Minipreps for
189 MiPreT were prepared by inoculating 5ml LB medium with *E. coli* colonies containing the
190 appropriate plasmid (rich media such as 2xYT are not suitable to reach good yields) in a 50ml
191 conical tube. *E. coli* were grown for 16-20 hours at 37°C, cells were pelleted and transferred into a
192 1.5ml tube, briefly spun and the remaining medium was removed. The pellet was loosened by
193 vigorous vortexing and bacteria were lysed by adding 400µl alkaline lysis buffer (0.1 M TrisHCl
194 pH 8.0, 0.1 M NaOH, 0.5 % SDS, 1 mM EDTA, with RNaseA added to 50µg/ml prior to use).
195 Tubes were inverted several times and vortexed briefly. Then 200µl 3M NaAcetate pH 5.3 was
196 added, the sample mixed well and centrifuged at maximum speed in a table top centrifuge for 5-10
197 minutes. The supernatant was transferred to a fresh tube and precipitated by adding 550µl
198 isopropanol, stored for 10 minutes and centrifuged for 20 minutes. The pellet was briefly dried,
199 resuspended in 100µl TE buffer and phenol/chloroform extracted followed by precipitation using
200 1/10 volume 3M NaAcetate pH 5.3 and 3 volumes 100% ethanol. DNA was pelleted by
201 centrifugation for 30 minutes and the pellet washed and sterilised using 75% ethanol. All the
202 following steps were performed in a laminar air flow cabinet. The 75% ethanol was removed and
203 the DNA pellet dried in the laminar air flow cabinet. The mini prep DNA pellet represents
204 approximately 40-60ug DNA. The pellet was then resuspended in 30µl TE, stored for 5 minutes and
205 700µl cytomix (Wu et al., 1995) were added. The parasite culture to be transfected was pelleted,
206 250µl of the packed cells were added to the DNA solution, mixed and transferred into a 0.4 cm
207 electroporation cuvette. Parasites were transfected using standard bacterial transformation
208 conditions as described (Wu et al., 1995). The transfected parasites were added to a fresh 60 mm
209 dish containing 6ml fresh media and one drop of uninfected blood to compensate for the lysis of red

210 blood cells. Transfected cultures were put on drug (WR99210 at 5nM concentration) 6-12 hours (or
 211 immediately) after transfection and fed every day until parasites had died off. Then the cultures
 212 were fed every second day until 1% parasitemia was reached.

213

214 **Fig. 2.** Genomic analysis of transfections. **A.** Southern blot illustrating the presence of pARL and
 215 ETRAMP4myc vectors in 3D7 and D10 transfected lines from MiPreT and MaxPreT transfections.
 216 **B.** Representative vector rescues from 3D7 pARL(MaxPreT) and D10 pARL(MiPreT) parasite
 217 lines. Both untransfected and rescued vector show the same restriction pattern (4687 and 2722bp).

218

219 **Fig. 3.** ETRAMP5myc and ETRAMP11.1myc transgene analysis of MiPreT transfected parasites
 220 using immunofluorescence assays. Cells were fixed with acetone and probed with an anti-myc
 221 serum (cy 2, green), co-stained with a serum detecting REX1 (TexasRed, red) localising to the
 222 Maurer's clefts (Hawthorne et al, 2004) and Hoechst nuclei staining (blue). Each panel shows 3
 223 representative cells from different sections. **A.** ETRAMP5myc parasites showing localization to the
 224 periphery of late ring and early trophozoite stage parasites. **B.** ETRAMP11.1myc parasite line with
 225 localization of the transgene to the periphery of ring stage parasites. Size bars, 5µm.

226

227

228 **Table 1. Side by side comparison of the mini preparation transfection protocol with the**
 229 **standard method using commercial maxi preparations.**

230

Plasmid	Maxi preparation protocol	Mini preparation protocol
ETRAPM4myc	29*(3D7), 26*(D10)	28*(3D7), 24*(D10)
pARL	22*(3D7), 31*(D10)	24*(3D7), 34*(D10)

231 * Days after transfection until 1% parasitemia was reached; parasite line used indicated in brackets

232

Figure 1





Figure 3.

